Press Release

Media Contact
Martin Kunze
T +49 6172 609-2115
martin.kunze@fresenius.com

Contact for analysts andinvestors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com

December 12, 2018

Unicyte AG to collaborate with Medical Center Hamburg-Eppendorf
on innovative treatments for patients with kidney disorders
Unicyte AG, a subsidiary of Fresenius Medical Care, has initiated a long-term researchcollaboration with Prof. Dr. Tobias B. Huber of Germany’s Medical Center HamburgEppendorf (UKE) to explore the molecular and cellular mechanisms of kidney diseases.
Prof. Huber, Chair of the III. Department of Medicine at UKE, a major university hospital,
is a leading expert on glomerular diseases. He will direct the research program, whichaims to address various forms of kidney disease including diabetic nephropathy. The
goals of the collaboration are to gain further insights into the process leading to thegradual decline in renal function and to identify genetic, signaling and soluble factors
involved in the underlying mechanisms.
Unicyte, a leading regenerative medicine company with translational programs in thefield of kidney disorders and other illnesses, is building on successful partnerships withother academic partners. These include a collaboration of 15 years’ standing with theUniversity of Torino in Italy.
Dr. Olaf Schermeier, Fresenius Medical Care’s CEO for Global Research and Development,
said: “As Unicyte’s organizational structure is designed to leverage the benefits ofacademia-industry partnerships, the collaboration with Prof. Huber offers a unique
opportunity to help patients with kidney disorders by developing innovative treatment
options based on a holistic understanding of renal dysfunction. I’m very excited about
this collaboration with one of the leading hospitals in Europe, as it could lead to newtreatment options that will complement current kidney care.”Page 1/2

Prof. Tobias B. Huber stated: “Because fundamental scientific questions concerning thepathomechanisms of kidney diseases remain to be answered, we will further explore thepotential of new options for the treatment of kidney patients in pre-dialysis stages. The
collaboration with Unicyte as industry partner will be fruitful in developing a therapy frompre-clinical research through to clinical practice. Our goal is to provide excellent new
therapies, reduce the burden of disease, and significantly improve the lives of ourpatients.”

Fresenius Medical Care is the world's largest provider of products and services for individuals
with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis
treatment. Through its network of 3,872 dialysis clinics, Fresenius Medical Care provides dialysis
treatments for 329,085 patients around the globe. Fresenius Medical Care is also the leading
provider of dialysis products such as dialysis machines or dialyzers. Along with its core business,the company provides related medical services in the field of Care Coordination. Fresenius Medical
Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company’s website at www.freseniusmedicalcare.com.
Unicyte AG is a regenerative medicine company with a focus on kidney & liver disorders, diabetes
and oncology. Unicyte evolved from a long-term research collaboration of Italy’s University of Turinand Fresenius Medical Care. Unicyte is headquarted in Oberdorf NW, Switzerland, and is anindependent affiliate of Fresenius Medical Care, the world's largest provider of products andservices for individuals with renal diseases.
For more information visit the company’s website at www.unicyte.ch.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual
results could differ materially from those described in these forward-looking statements due to certain factors,
including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate
fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These andother risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S.
Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this release.

Page 2/2